Different power modes of microwave ablation for hepatocellular carcinoma: Evaluation of recurrence rate and factors related to recurrence

被引:2
|
作者
Dong, Tiantian [1 ,2 ,3 ]
Nie, Fang [1 ,2 ,3 ]
Liu, Ting [1 ,2 ,3 ]
Wang, Lan [1 ,2 ,3 ]
Yang, Dan [1 ,2 ,3 ]
Yan, Xueliang [1 ,2 ,3 ]
机构
[1] Lanzhou Univ, Ultrasound Med Ctr, Hosp 2, Cuiyingmen 82, Lanzhou 730030, Gansu, Peoples R China
[2] Gansu Prov Clin Res Ctr Ultrasonog, Lanzhou, Peoples R China
[3] Gansu Prov Med Engn Res Ctr Intelligence Ultrasoun, Lanzhou, Peoples R China
关键词
Microwave ablation; Hepatocellular carcinoma; Tumor progression; Contrast-enhanced ultrasound; RADIOFREQUENCY ABLATION; LIVER METASTASES; TUMOR ABLATION; DIAPHRAGM;
D O I
10.1016/j.asjsur.2023.03.070
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: To evaluate the safety and efficacy of different power modes(constant power and variable power) percutaneous microwave ablation (MWA) for treating hepatocellular carcinoma (HCC) and to predict the risk factors of recurrence after MWA. Materials and methods: In this retrospective study, a total of 112 patients with solitary HCC were included from January 2015 to January 2021. All patients received MWA through a percutaneous approach that was guided by ultrasound, 45 patients received variable power MWA, and the remaining 67 were treated with constant power MWA. The complete ablation rates, local recurrence rates, complications, and short-term survival were analyzed. Possible risk factors for tumor recurrence were analyzed. Results: The complete ablation rates were 95.9% for the first ablation and 100% for the second ablation for <3 cm lesions. The complete ablation rates were 84.2%(95.9% versus 84.2%, p = 0.039) for the first ablation and 94.7% (100% versus 94.7%, p = 0.113) for the second ablation for 3-5 cm lesions. Local and distant recurrence rates were 18.7%(21/112) and 14.3%(16/112). The 1-, 2-year survival rates were 86.3 and 66.3%, respectively. Subgroup analysis showed that 1-, 2-year survival rates were 91.1% and 78.5% in <3 cm group, and were 74.4% and 40.9% in 3-5 cm group, respectively. Univariate analysis revealed that a positive correlation existed between the HBV DNA replication(p = 0.007), AFP level of pre-MWA(p = 0.001) and post-MWA(p<0.001), tumor diameter(p<0.001), irregular shape(p = 0.014), proximity to the risk location(p = 0.008), poor differentiation(p = 0.003), constant power(p = 0.028), length(p<0.001) and width of ablation zone(p = 0.001), and present complication(p<0.001), and early recurrence. Multivariate analysis identified HBV DNA replication(OR = 0.266, p = 0.036), AFP level of pre-MWA (OR = 4.001, p = 0.036), tumor diameter (OR = 2.153, p = 0.042), tumor location (OR = 0.910, p = 0.046), and width of ablation zone(OR = 2.530, p = 0.044) were independent prognosis factors causing postoperative HCC recurrence.Conclusion: Variable power MWA of HCC appears to be a safe and effective treatment. HBV DNA, AFP level of pre-MWA, tumor diameter, tumor location, and width of ablation range appear to be indepen-dent predictors of tumor recurrence.
引用
收藏
页码:3520 / 3528
页数:9
相关论文
共 50 条
  • [41] The safety and utility of biopsy during radiofrequency and microwave ablation for hepatocellular carcinoma in predicting tumour recurrence
    Gill, M.
    Tse, E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 101 - 102
  • [42] PREDICTING FACTORS OF LOCAL RECURRENCE AFTER CURATIVE PERCUTANEOUS RADIOFRECUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA
    Tamaki, N.
    Yasui, Y.
    Tsuchiya, K.
    Kurosaki, M.
    Asahina, Y.
    Izumi, N.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S406 - S406
  • [43] ARID1A expression in hepatocellular carcinoma and relation to tumor recurrence after microwave ablation
    Abdel-Moety, Aly
    Baddour, Nahed
    Salem, Perihan
    Rady, Amr
    El-Shendidi, Assem
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 8 (01) : 49 - 59
  • [44] Recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: Analysis of the pattern and risk factors
    Chen, Rui
    Hou, Beining
    Zhou, Yanzhao
    Zhang, Tuo
    Wang, Zhengzheng
    Chen, Xun
    Zhang, Yingwei
    Chen, Man
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [45] Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation
    Siripongsakun, Surachate
    Wei, Sindy H.
    Lin, Stephanie
    Chen, Jeffrey
    Raman, Steven S.
    Sayre, James
    Tong, Myron J.
    Lu, David S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (01) : 157 - 164
  • [46] Recurrence of Hepatocellular Carcinoma after Liver Transplantation: Recurrence Characteristics and Risk Factors
    Li, Chuan
    Wen, Tian-Fu
    Liao, Zhi-Xue
    Yan, Lv-Nan
    Li, Bo
    Zeng, Yong
    Wang, Wen-Tiao
    Xu, Ming-Qing
    Yang, Jia-Ying
    Wei, Yong-Gang
    HEPATO-GASTROENTEROLOGY, 2010, 57 (99-100) : 567 - 570
  • [47] Related Factors of Hepatocellular Carcinoma Recurrence Associated With Hyperglycemia After Liver Transplantation
    Zheng, Yujian
    Cai, Qing
    Peng, Lishan
    Sun, Shibo
    Wang, Shaoping
    Zhou, Jie
    TRANSPLANTATION PROCEEDINGS, 2021, 53 (01) : 177 - 192
  • [48] Recurrence of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA)
    Tateishi, R
    Shiina, S
    Teratani, T
    Hamamura, K
    Obi, S
    Sato, S
    Koike, Y
    Akamatsu, M
    Fujishima, T
    Ishikawa, T
    Shiratori, Y
    Omata, M
    GASTROENTEROLOGY, 2002, 122 (04) : A663 - A663
  • [49] Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma
    Ganne-Carrie, Nathalie
    Nault, Jean-Charles
    Ziol, Marianne
    N'Kontchou, Gisele
    Nahon, Pierre
    Grando, Veronique
    Bourcier, Valerie
    Barge, Sandrine
    Beaugrand, Michel
    Trinchet, Jean-Claude
    Seror, Olivier
    HEPATIC ONCOLOGY, 2014, 1 (04) : 395 - 408
  • [50] Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma
    Kang, Tae Wook
    Lim, Hyo Keun
    Cha, Dong Ik
    CLINICAL AND MOLECULAR HEPATOLOGY, 2017, 23 (01) : 95 - 101